On October 19, 2015 Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced that it has successfully completed the acquisition of AqueSys, Inc.
Allergan acquired AqueSys in an all-cash transaction, including a $300 million up-front payment and potential regulatory approval and commercialization milestone payments related to AqueSys' lead development product, XEN45.
Learn more about the combination at Allergan.com.
Ron Bache, President and CEO: “AqueSys is absolutely focused on exponentially improving the glaucoma treatment paradigm through minimally invasive technology that delivers significant efficacy. We provide surgeons with better treatment options that allow them peace of mind, and enable them to enhance their patients’ quality of life.”
Founded in 2006, AqueSys, Inc. is a privately-held, venture capital funded ophthalmic company headquartered in Orange County, California. The Company is focused on innovating and commercializing implantable devices that will significantly improve the treatment of glaucoma. Glaucoma is the world’s leading cause of irreversible blindness, and to in order to stop vision loss, significant efficacy must be provided. The minimally invasive AqueSys technology has the potential to shift the global treatment patterns of the $5 billion global market.
It has been said that “simplicity is the greatest sophistication.” AqueSys has created the world's first technology that utilizes the same proven mechanism of action as today’s traditional glaucoma procedures, but through a minimally invasive ab interno procedure that is similar to an injection.
Once in the eye, a single, soft but permanent, gelatin stent is designed to safely provide significant, long-term IOP control, which may reduce the risk of further vision loss due to glaucoma.